Le Lézard
Classified in: Health
Subject: FVT

Using Cognition to Understand Effects of Medicines Used to Optimize Sleep or Wakefulness, Upcoming Webinar Hosted by Xtalks


In this free webinar, learn about the importance of measuring cognition in sleep medicine trials. Attendees will gain insights into the nature and magnitude of cognitive impairment that can occur in sleep medicine drug development. The featured speaker will discuss how cognitive tests can be used to better inform decision-making on safety and efficacy of novel and licensed drugs.

TORONTO, April 10, 2024 /PRNewswire-PRWeb/ -- Disruption to normal sleep/wake cycles results in substantial disability and loss of productivity. Sleep/wake cycle dysfunction can also increase morbidity and mortality and therefore remains an urgent target for the development of medicines that can ameliorate such dysfunction.

In the field of sleep medicine, the meaning of changes in cognition can be communicated using various terms such as fatigue, drowsiness, sleepiness, sedation, diminished alertness and diminished attention.

In the field of sleep medicine, the meaning of changes in cognition can be communicated using various terms such as fatigue, drowsiness, sleepiness, sedation, diminished alertness and diminished attention. Such variability reduces the ability of clinical teams to make decisions about the nature and magnitude of cognitive impairment in disorders of the sleep/wake cycle, the effects of sedative and alerting drugs in experimental medicine models and the best approach to utilize cognitive information in late-phase clinical trials.

In this webinar, Prof. Paul Maruff will utilize published cognitive test data obtained from many clinical trials and provide a framework for understanding the nature and magnitude of cognitive impairment that can occur in sleep medicine drug development. Data are obtained from trials of patients with disrupted sleep/wake cycles, healthy adults who have received medicines with sedative effects and healthy adults who have undergone long periods of sleep restriction. This framework will help research teams make informed decisions about the safety and efficacy of novel and licensed drugs in drug development programs.

Register for this webinar today to discover how data on cognition can provide insights into the cognitive impairment that may arise in sleep medicine drug development.

Join Paul Maruff, PhD, Chief Innovation Officer, Cogstate, for the live webinar on Tuesday, April 30, 2024, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Using Cognition to Understand Effects of Medicines Used to Optimize Sleep or Wakefulness.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/

Media Contact

Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com 

SOURCE Xtalks


These press releases may also interest you

at 18:54
Immunovia carries out a rights issue of units of approximately SEK 70 million and raises bridge loans
The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has today,...

at 18:12
Functional Food Ingredients Market size is set to grow by USD 53.14 bn from 2024-2028, increased demand for functional food ingredients from probiotics segment to boost the market growth, Technavio
The global functional food ingredients market size is estimated to grow by USD 53.14 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 7.38% during the forecast period. ...

at 17:55
City of Hope Awarded $5.4 Million CIRM Grant to Create a Stem Cell Laboratory and Expand Access to State-of-the-Art Disease Models and Technology Among a Diverse Scientific Community
City of Hope®, one of the largest cancer research and treatment organizations in the United States, has been awarded $5.4 million from the California Institute for Regenerative Medicine (CIRM) to build and fund a stem cell research laboratory on its...

at 17:25
Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Talphera, Inc. , ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Board of Directors of Talphera has granted...

at 16:56
JDRF-Authored Paper Shows Pathway to Accelerate Disease-Modifying Therapies for People with Type 1 Diabetes
A paper published in the June edition of the Journal Diabetes demonstrates that C-peptide, a biomarker that indicates the production of insulin, is a validated surrogate endpoint, or predictor of clinical benefit, for clinical trials of...

at 16:28
Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session
?Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs. Macrolide-Based Background Regimen Alone, As Measured By the QOL-B Respiratory Domain Instrument? ?QOL-B...

More news about Health...


News published on and distributed by: